CLIENT NEWS
- InflaRx Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients31 March 2022
- Data on the antimicrobial activity of XF-73 against bacteria within biofilms to be presented at prestigious 2022 ECCMID Congress31 March 2022
- HepaRegeniX appoints Elias Papatheodorou as new Chairman of the Board of Directors30 March 2022
- Adocia strengthens its cash position by 19 million euros following a real estate transaction28 March 2022
- Atriva Therapeutics announces efficacy of its lead compound zapnometinib against Omicron28 March 2022
- InflaRx Reports Full Year 2021 Financial and Operating Results24 March 2022
- Heidelberg Pharma Announces Financial Figures for Fiscal Year 2021 and Provides Business Update24 March 2022
- Atriva Therapeutics announces changes in its Management Team22 March 2022
- InflaRx Receives Corrected Advice Letter from FDA Related to Phase III Program for Vilobelimab in Hidradenitis Suppurativa17 March 2022
- Abivax reports 2021 financial results and operations update16 March 2022